A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism in this randomized controlled trial publication.

Direct comparison of cinacalcet and vitamin D analogs as monotherapies to lower parathyroid hormone (PTH) levels has not been undertaken.

A preplanned analysis to determine whether there were important region-by-treatment interactions was also undertaken.

Who Took Part

By PubMed's age tags, the people studied were older adults and people over 80, both men and women.

This was a prospective, multicenter, phase 4, randomized, open-label study that enrolled participants from 2010 to 2012.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

More than one site took part, so the participants came from several places.

What Was Measured

Topics PubMed links to this paper include Australia, Biomarkers, Calcimimetic Agents, Canada, Cinacalcet, Hyperparathyroidism, Secondary and Kidney Failure, Chronic.

Author keywords: CKD, ESRD and dialysis.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.